Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Estrogen Receptor Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00365599
What this trial is testing

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Who this might be right for
Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 43
Testing effectiveness (Phase 2)Active Not RecruitingNCT05607004
What this trial is testing

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

Who this might be right for
Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast Cancer+1 more
Atossa Therapeutics, Inc. 87
Testing effectiveness (Phase 2)Study completedNCT01972984
What this trial is testing

Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients

Who this might be right for
Breast Cancer
Ottawa Hospital Research Institute 20
Not applicableStudy completedNCT02625935
What this trial is testing

Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients

Who this might be right for
Breast Cancer
NanoString Technologies, Inc. 206
Early research (Phase 1)Study completedNCT02392611
What this trial is testing

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Who this might be right for
Solid Tumors and Lymphomas
Gilead Sciences 33
Early research (Phase 1)Study completedNCT02338349
What this trial is testing

A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Who this might be right for
Advanced ER+, HER2-Negative Breast Cancer
Stemline Therapeutics, Inc. 57
Not applicableStudy completedNCT01611038
What this trial is testing

Methylselenocysteine Effects on Circadian Rhythm

Who this might be right for
Breast CancerProstate Cancer
Rutgers, The State University of New Jersey 100
Post-approval studies (Phase 4)Ended earlyNCT05183828
What this trial is testing

Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+2 more
University of Washington 62
Early research (Phase 1)Ended earlyNCT01149356
What this trial is testing

RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveHER2/Neu NegativeMale Breast Carcinoma+4 more
National Cancer Institute (NCI) 15
Early research (Phase 1)Study completedNCT01344031
What this trial is testing

MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor PositiveInvasive Breast CarcinomaRecurrent Breast Carcinoma+1 more
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774
What this trial is testing

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 84
Testing effectiveness (Phase 2)Study completedNCT00733408
What this trial is testing

Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerProgesterone Receptor-negative Breast Cancer+3 more
University of Washington 59
Testing effectiveness (Phase 2)Ended earlyNCT01430585
What this trial is testing

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Who this might be right for
Early Breast Cancer (Phase 2)Advanced Breast Cancer (Phase 1b)
Pfizer 14
Early research (Phase 1)Study completedNCT04080297
What this trial is testing

Dose Escalation Study in Female Subjects With Breast Cancer Receiving Aromatase Inhibitor or Tamoxifen

Who this might be right for
Vasomotor Symptoms (VMS)
Que Oncology 21
Early research (Phase 1)Ended earlyNCT02414776
What this trial is testing

Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy

Who this might be right for
Estrogen Receptor Positive Breast Cancer
Western Regional Medical Center 3
Not applicableStudy completedNCT00072293
What this trial is testing

Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases

Who this might be right for
Breast Cancer
ETOP IBCSG Partners Foundation 931
Testing effectiveness (Phase 2)UnknownNCT00687648
What this trial is testing

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Centre, Singapore 70
Testing effectiveness (Phase 2)Study completedNCT00632723
What this trial is testing

IRESSA™ (Gefitinib) in Breast Cancer Patients

Who this might be right for
Breast Cancer
AstraZeneca 54
Testing effectiveness (Phase 2)Ended earlyNCT03709082
What this trial is testing

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast Cancer Metastatic
University of Kansas Medical Center 3
Not applicableActive Not RecruitingNCT01996046
What this trial is testing

FDG PET/CT in Breast Cancer Bone Mets

Who this might be right for
Estrogen Receptor Positive Breast CancerBone Metastases
University of Pennsylvania 75
Next Page